Market Research Logo

Global Congestive Heart Failure Drugs Market 2015-2019

Global Congestive Heart Failure Drugs Market 2015-2019

About Congestive Heart Failure Drugs

Congestive heart failure is a serious and complex condition in which the heart muscles are either damaged or have to work too hard. Although the heart beats, the damaged heart muscles are too weak to pump sufficient oxygen-rich blood to and from the body. ACE inhibitors/ARB antagonists, beta-adrenergic receptor blocking agents, diuretics, and inotropic drugs are the medications available for the treatment of congestive heart failure.

TechNavio's analysts forecast the Global Congestive Heart Failure Drugs market to grow at a CAGR of 9.47 percent over the period 2014-2019.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global Congestive Heart Failure Drugs market for the period 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of approved drugs and generics used in the treatment of congestive heart failure that are available in the market. The Global Congestive Heart Failure Drugs market can be divided into four segments: ACE Inhibitors/ARB Antagonists, Beta-adrenergic Receptor Blocking Agents, Diuretics, and Inotropic Drugs/Vasodilators.

TechNavio's report, the Global Congestive Heart Failure Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the APAC and EMEA regions; it also covers the Global Congestive Heart Failure Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • APAC
  • EMEA
Key Vendors
  • AstraZeneca
  • Bristol-Myers Squibb
  • GSK
  • Merck & Co.
  • Mylan
  • Novartis
  • Pfizer
  • Sanofi
  • Valeant Pharmaceuticals
Other Prominent Vendors
  • Bayer
  • Bioheart
  • Boehringer Inhelheim
  • Takeda Pharmaceutical
  • Teva Pharmaceutical Industries
Market Driver
  • Increase in Aging Population
  • For a full, detailed list, view our report
Market Challenge
  • Weak Pipeline
  • For a full, detailed list, view our report
Market Trend
  • Increase in Awareness
  • For a full, detailed list, view our report
Key Questions Answered in this Report
  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

TechNavio Announces the Publication of its Research Report – Global Congestive Heart Failure Drugs Market 2015-2019

TechNavio recognizes the following companies as the key players in the Global Congestive Heart Failure Drugs Market: AstraZeneca plc, Bristol-Myers Squibb Co., GlaxoSmithKline plc (GSK), Merck & Co. Inc., Mylan Inc., Novartis AG, Pfizer Inc., Sanofi SA and Valeant Pharmaceuticals International Inc.

Other Prominent Vendors in the market are: Bayer, Bioheart, Boehringer Ingelheim, Takeda Pharmaceutical and Teva Pharmaceutical Industries.

Commenting on the report, an analyst from TechNavio’s team said: “One major trend witness in this market is the increase in awareness. The acceptability of congestive heart failure drugs is expected to increase because of the increase in public awareness. Patients and physicians are becoming more aware about congestive heart failure.”

According to the report, one of the main drivers of this market is the increase in the aging population. The elderly in both developing and developed countries have an increased risk of developing congestive heart failure and other ailments.

Further, the report states that one of the main challenges that the market faces is the weak drug pipeline. The market lacks promising pipeline molecules to address the unmet needs in the market. Therefore, new drugs in the pipeline will not have any effect on the growth of the market.

Companies Mentioned

AstraZeneca, Bristol-Myers Squibb, GSK, Merck & Co., Mylan, Novartis, Pfizer, Sanofi, Valeant Pharmaceuticals, Bayer, Bioheart , Boehringer Inhelheim , Takeda Pharmaceutical , Teva Pharmaceutical Industries

  • Executive Summary
  • List of Abbreviations
  • Scope of the Report
    • Market Overview
    • Product Offerings
      • Product Profiles
  • Market Research Methodology
    • Market Research Process
    • Research Methodology
      • Table Market Research Methodology
  • Introduction
  • Market Landscape
    • Market Overview
    • Market Size and Forecast
      • Table Global Congestive Heart Failure Drugs Market 2014-2019 (US$ billion)
    • Five Forces Analysis
  • Market Segmentation by Therapeutic Class
    • Segmentation of Global Congestive Heart Failure Drugs Market by Therapeutic Class
      • Table Segmentation of Global Congestive Heart Failure Drugs Market by Therapeutic Class
  • Late Stage Pipeline Molecules
    • Table Clinical Development Pipeline for Congestive Heart Failure
  • Geographical Segmentation
    • Segmentation of Global Congestive Heart Failure Drugs Market by Geography 2014-2019
      • Table Segmentation of Global Congestive Heart Failure Drugs Market by Geography 2014
    • Congestive Heart Failure Drugs Market in Americas
      • Market Size and Forecast
        • Table Congestive Heart Failure Drugs Market in Americas 2014-2019 (US$ billion)
    • Congestive Heart Failure Drugs Market in Europe
      • Market Size and Forecast
        • Table Congestive Heart Failure Drugs Market in Europe 2014-2019 (US$ billion)
    • Congestive Heart Failure Drugs Market in Asia
      • Market Size and Forecast
        • Table Congestive Heart Failure Drugs Market in Asia 2014-2019 (US$ billion)
    • Congestive Heart Failure Drugs Market in ROW
      • Market Size and Forecast
        • Table Congestive Heart Failure Drugs Market in ROW 2014-2019 (US$ billion)
        • Table Segmentation of Global Congestive Heart Failure Drugs Market by Geography 2014-2019
        • Table Segmentation of Global Congestive Heart Failure Drugs Market by Geography 2014-2019 (US$ billion)
  • Buying Criteria
  • Market Growth Drivers
    • Table Estimated Prevalence of Congestive Heart Failure in Different Age Groups in US
  • Drivers and their Impact
  • Market Challenges
  • Impact of Drivers and Challenges
  • Market Trends
  • Trends and their Impact
  • Vendor Landscape
    • Competitive Scenario
      • Key News
      • Mergers and Acquisitions
    • Market Share Analysis 2014
      • Table AstraZeneca: Revenue 2010-2013 (US$ billion)
      • Table GSK: Revenue 2010-2013 (US$ billion)
      • Table GSK: Global Sales of Medicines by Therapeutic Class 2013
      • Table GSK: Revenue of Coreg 2010-2013 (US$ billion)
      • Table Merck: Revenue 2010-2013 (US$ billion)
      • Table Mylan: Revenue 2010-2013 (US$ billion)
      • Table Novartis: Revenue of Diovan 2010-2013 (US$ billion)
      • Table Novartis: Revenue 2010-2013 (US$ billion)
      • Table Pfizer: Revenue 2010-2013 (US$ billion)
      • Table Sanofi: Revenue 2010-2013 (US$ billion)
      • Table Valeant: Revenue 2010-2013 (US$ billion)
      • Table Valeant: Segmentation of Revenue by Product
    • Other Prominent Vendors
  • Key Vendor Analysis
    • AstraZeneca plc
      • Key Facts
      • Business Overview
      • Business Segmentation by Revenue 2013
        • Table AstraZeneca plc: Business Segmentation by Revenue 2013
      • Business Segmentation by Revenue 2011-2013
        • Table AstraZeneca plc: Business Segmentation by Revenue 2011-2013 (US$ million)
      • Sales by Geography
        • Table AstraZeneca plc: Sales by Geography 2013
      • Business Strategy
      • Key Developments
      • SWOT Analysis
    • Bristol-Myers Squibb Co.
      • Key Facts
      • Business Overview
      • Key Product Offerings
        • Table Bristol-Myers Squibb Co.: Key Product Offerings (Based on Therapeutic Areas)
      • Revenue by Geography
        • Table Bristol-Myers Squibb Co.: Revenue by Geographical Segmentation 2013
      • Business Strategy
      • Key Information
      • SWOT Analysis
    • GlaxoSmithKline
      • Key Facts
      • Business Overview
      • Business Segmentation
        • Table GlaxoSmithKline: Business Segmentation 2013
      • Business Segmentation by Revenue 2012 and 2013
        • Table GlaxoSmithKline: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
      • Sales by Geography
        • Table GlaxoSmithKline: Sales by Geography 2013
      • Pipeline Products
        • Table GlaxoSmithKline: Pipeline Products 2013
      • Business Strategy
      • Key Information
      • SWOT Analysis
    • Merck & Co. Inc.
      • Key Facts
      • Business Overview
      • Business Segmentation by Revenue 2013
        • Table Merck & Co. Inc.: Business Segmentation by Revenue 2013
      • Business Segmentation by Revenue 2012 and 2013
        • Table Merck & Co. Inc.: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
      • Sales by Geography
        • Table Merck & Co. Inc.: Sales by Geography 2013
      • Business Strategy
      • Key Developments
      • SWOT Analysis
    • Mylan
      • Key Facts
      • Business Overview
      • Business Segmentation by Revenue 2013
        • Table Global Military Laser Systems Market 2015-2019: Business Segmentation by Revenue 2013
      • Business Segmentation by Revenue 2011-2013
        • Table Small Arms Market in the US 2015-2019: Business Segmentation by Revenue 2011-2013 (US$ billion)
      • Geographical Segmentation by Revenue 2013
        • Table Shoulder-fired Weapons Market in North America 2015-2019: Geographical Segmentation by Revenue 2013
      • Business Strategy
      • Recent Developments
      • SWOT Analysis
    • Novartis AG
      • Key Facts
      • Business Description
      • Business Segmentation
        • Table Novartis AG: Business Segmentation
      • Revenue by Business Segmentation
        • Table Novartis AG: Revenue by Business Segmentation 2013
      • Revenue Comparison 2012 and 2013
        • Table Novartis AG: Revenue by Business Segmentation 2012 and 2013 (US$ million)
      • Sales by Geography
        • Table Novartis AG: Revenue by Geographical Segmentation 2013
      • Business Strategy
      • Key Developments
      • SWOT Analysis
    • Pfizer
      • Key Facts
      • Business Overview
      • Business Segmentation by Revenue 2013
        • Table Pfizer: Business Segmentation by Revenue 2013
      • Business Segmentation by Revenue 2012 and 2013
        • Table Pfizer: Business Segmentation by Revenue 2012 and 2013
      • Geographical Segmentation by Revenue
        • Table Pfizer: Geographical Segmentation by Revenue 2013
      • Business Strategy
      • Key Developments
      • SWOT Analysis
    • Sanofi SA
      • Key Facts
      • Business Description
      • Business Segmentation
        • Table Sanofi SA: Business Segmentation
      • Revenue by Business Segmentation
        • Table Sanofi SA: Revenue by Business Segmentation 2013
      • Revenue Comparison 2012 and 2013
        • Table Sanofi SA: Revenue by Business Segmentation 2012 and 2013 (US$ million)
      • Sales by Geography
        • Table Sanofi SA: Sales Revenue by Geographical Segmentation 2013
      • Business Strategy
      • Key Developments
      • SWOT Analysis
    • Valeant Pharmaceuticals International
      • Key Facts
      • Business Overview
      • Business Segmentation by Revenue 2013
        • Table Valeant Pharmaceuticals International: Business Segmentation by Revenue 2013
      • Business Segmentation by Revenue 2012 and 2013
        • Table Valeant Pharmaceuticals International: Business Segmentation by Revenue 2012 and 2013 (US$ million)
      • Sales by Geography
        • Table Valeant Pharmaceuticals International: Sales by Geography 2013
      • Business Strategy
      • Key Developments
      • SWOT Analysis
  • Other Reports in this Series

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report